Childhood acute lymphoblastic leukemia: modified BFM-2009 protocol

Childhood acute lymphoblastic leukemia: modified BFM-2009 protocol

Paediatrics · Oncology

Childhood acute lymphoblastic leukemia (ALL) is the most common hematological malignancy in children and is characterized by the uncontrolled proliferation of immature lymphoid cells in the bone marrow. Advances in multiagent chemotherapy, risk stratification, and supportive care have substantially improved treatment outcomes. The Berlin-Frankfurt-Münster (BFM)-2009 protocol provides a structured, risk-adapted treatment approach that incorporates early treatment response and measurable residual disease (MRD) assessment to guide therapeutic intensity. Modified BFM-2009 protocols have been adapted in different treatment centers to address patient characteristics, treatment-related toxicity, and resource availability, particularly in low- and middle-income countries. These modifications aim to maintain disease control while improving treatment feasibility and reducing preventable complications.[1][2]Treatment principles of the modified BFM-2009 protocolThe protocol follows a multi-phase chemotherapy approach designed to achieve complete remission, eliminate residual leukemic cells, and prevent disease relapseTreatment intensity is individualized according to clinical characteristics, immunophenotype, cytogenetic findings, and early response to chemotherapyPatients are generally categorized into standard-risk, intermediate-risk, and high-risk groups to guide subsequent treatment intensityMRD assessment using multiparameter flow cytometry or molecular techniques provides additional information about treatment response and residual leukemia[1][2]Risk stratification and treatment allocationInitial risk assessment incorporates age at diagnosis, presenting white blood cell count, immunophenotype, and relevant cytogenetic or molecular abnormalitiesEarly treatment response is evaluated through peripheral blood blast counts following the corticosteroid prephase and bone marrow assessment during inductionMRD measurements at defined treatment time points help identify patients with persistent leukemic disease despite morphological remissionPatients demonstrating favorable early responses are generally assigned to standard-risk treatment, whereas poor responders and those with adverse biological features may require intensified therapy[1][2]Major phases of treatmentPrephase: Initial corticosteroid therapy is administered to reduce leukemic burden and assess early treatment response before multiagent inductionInduction: Combination chemotherapy using agents such as Prednisolone, Vincristine, Daunorubicin, and Asparaginase aims to achieve morphological remissionConsolidation: Additional chemotherapy, commonly incorporating Cyclophosphamide, Cytarabine, and Mercaptopurine, targets residual leukemic cells and reduces relapse riskInterim maintenance: Methotrexate-based treatment helps maintain disease control between intensive treatment phasesReinduction: A subsequent intensive treatment phase reinforces remission and targets persistent leukemic cellsMaintenance: Prolonged treatment, commonly involving Mercaptopurine and Methotrexate, helps sustain remission and prevent disease recurrence[1][2]Monitoring and supportive careBone marrow morphology and MRD assessment are important for evaluating remission status and identifying inadequate treatment responseComplete blood counts, liver function, renal function, and metabolic parameters should be monitored throughout chemotherapyTreatment-related complications, including febrile neutropenia, infections, mucositis, hepatotoxicity, and pancreatitis, require timely recognition and managementTransfusion support, antimicrobial treatment, nutritional support, and appropriate infection-prevention measures contribute to treatment continuityAdherence to chemotherapy schedules and regular assessment of treatment toxicity are essential components of protocol implementation[1][3]Important considerations during protocol implementationClinical considerationRelevance to treatmentImmunophenotypingEstablishes B-cell or T-cell lineage and supports treatment classification.Cytogenetic evaluationIdentifies genetic abnormalities associated with favorable or adverse prognosis.MRD availabilitySupports response-based risk classification and treatment adaptation.Treatment-related mortalityHighlights the importance of infection control and supportive care.Treatment adherenceHelps minimize interruptions and reduce the risk of relapse.ConclusionThe modified BFM-2009 protocol provides a structured, risk-adapted approach to managing childhood ALL through sequential chemotherapy phases, early response assessment, and MRD-guided treatment allocation. Its adaptation to local clinical settings may improve treatment feasibility while maintaining the essential principles of leukemia control. Accurate risk classification, appropriate treatment intensity, toxicity monitoring, and comprehensive supportive care remain central to achieving favorable outcomes. However, specific modifications vary between institutions, and treatment should follow the validated protocol adopted by the treating pediatric hematology-oncology center.Reference(s):1. Hayashi H, Makimoto A, Yuza Y. Treatment of Pediatric Acute Lymphoblastic Leukemia: A Historical Perspective. Cancers (Basel). 2024;16(4):723. Published 2024 Feb 8. doi:10.3390/cancers16040723. https://pubmed.ncbi.nlm.nih.gov/38398113/2. Pawinska-Wasikowska K, Bukowska-Strakova K, Surman M, et al. Go with the Flow-Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009. Cancers (Basel). 2022;14(21):5359. Published 2022 Oct 30. doi:10.3390/cancers14215359. https://pmc.ncbi.nlm.nih.gov/articles/PMC9653819/3. Kumar K, Singh SK, Nayak J, et al. Outcome of Childhood and Adolescents and Young Adults ALL Treated with ALL IC-BFM 2009 Protocol-A Single-Center Experience in India. Indian J Hematol Blood Transfus. 2025;41(3):494-503. doi:10.1007/s12288-024-01898-5. https://pubmed.ncbi.nlm.nih.gov/40687470/